US Stock MarketDetailed Quotes

PEN Penumbra

Watchlist
  • 285.440
  • +3.980+1.41%
Close Feb 28 16:00 ET
  • 285.440
  • 0.0000.00%
Post 20:01 ET
10.99BMarket Cap792.89P/E (TTM)

About Penumbra Company

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Company Profile

SymbolPEN
Company NamePenumbra
Listing DateSep 18, 2015
Issue Price30.00
Founded2004
CEOMr. Adam Elsesser
MarketNYSE
Employees4500
Fiscal Year Ends12-31
AddressOne Penumbra Place
CityAlameda
ProvinceCalifornia
CountryUnited States of America
Zip Code94502
Phone1-510-748-3200

Company Executives

  • Name
  • Position
  • Salary
  • Adam Elsesser
  • Chief Executive Officer, President and Chairman of the Board
  • 601.62K
  • Lambert Shiu
  • Chief Accounting Officer
  • 539.94K
  • Maggie Yuen
  • Chief Financial Officer
  • 666.04K
  • Johanna Roberts
  • Executive Vice President, General Counsel and Secretary
  • 661.89K
  • Dr. Arani Bose, M.D.
  • Director
  • 233.99K
  • Surbhi Sarna
  • Independent Director
  • 248.99K
  • Bridget O'Rourke
  • Independent Director
  • 263.99K
  • Don Kassing
  • Presiding Independent Director
  • 246.49K
  • Janet Leeds
  • Independent Director
  • 251.49K
  • Harpreet Grewal
  • Independent Director
  • 241.49K
  • Thomas C. Wilder, III
  • Independent Director
  • 258.99K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.